21 – 30 of 63
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
- Contribution to journal › Article
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
- Contribution to journal › Article
- 2023
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
- Contribution to journal › Article
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
- Contribution to journal › Article
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
- Contribution to journal › Scientific review
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
- Contribution to journal › Article
-
Mark
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
- Contribution to journal › Article
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
- Contribution to journal › Article
